Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRD1 | P41143 | 18/20 | 0.70 |
| ▸ | OPRM1 | P35372 | 16/20 | 0.70 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.66 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.66 |
| ▸ | OPRK1 | P41145 | 6/20 | 0.65 |
| ▸ | GAA | P10253 | 1/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.52 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5760596 | 0.85 | OPRD1 (0.71) | OPRD1OPRM1KCNH2ABCB11OPRK1 | |
| SCHEMBL5789652 | 0.85 | OPRD1 (0.72) | OPRD1OPRM1KCNH2ABCB11OPRK1 | |
| SCHEMBL5789722 | 0.84 | OPRD1 (0.69) | OPRD1OPRM1KCNH2ABCB11OPRK1 | |
| SCHEMBL5373699 | 0.83 | OPRD1 (0.83) | OPRD1OPRM1KCNH2ABCB11OPRK1 | |
| SCHEMBL4929150 | 0.83 | OPRD1 (1.00) | OPRD1OPRM1KCNH2ABCB11OPRK1 | |
| SCHEMBL5760146 | 0.83 | OPRD1 (0.73) | OPRD1OPRM1KCNH2ABCB11OPRK1 | |
| SCHEMBL5758234 | 0.82 | OPRD1 (0.66) | OPRD1OPRM1KCNH2ABCB11OPRK1 | |
| SCHEMBL6078488 | 0.82 | OPRD1 (0.64) | OPRD1OPRM1KCNH2ABCB11OPRK1 | |
| SCHEMBL5793217 | 0.82 | OPRD1 (0.64) | OPRD1OPRM1KCNH2ABCB11OPRK1 | |
| SCHEMBL5365299 | 0.82 | OPRD1 (0.81) | OPRD1OPRM1KCNH2ABCB11OPRK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060079555-A1 | Diarylmethylidene piperidine derivatives, preparations thereof and uses thereof | ASTRAZENECA AB (SE) | 2006-04-13 | — | — | US | claimed |
| EP-1613593-A1 | DIARYLMETHYLIDENE PIPERIDINE DERIVATIVES, PREPARATIONS THEREOF AND USES THEREOF | AstraZeneca AB (SE) | 2006-01-11 | — | — | EP | claimed |
| WO-2004087663-A1 | DIARYLMETHYLIDENE PIPERIDINE DERIVATIVES, PREPARATIONS THEREOF AND USES THEREOF | ASTRAZENECA AB (SE) | 2004-10-14 | — | — | WO | claimed |
| US-20060079555-A1 | Diarylmethylidene piperidine derivatives, preparations thereof and uses thereof | ASTRAZENECA AB (SE) | 2006-04-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060079555-A1 | Diarylmethylidene piperidine derivatives, preparations thereof and uses thereof | OPRM1, OPRD1, OPRL1 | OPRD1 2/4885OPRM1 1/4885KCNH2 56/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.